Table 4.
Major Ongoing Clinical Trials
| Trial | Condition | Cell Type | Route | Time Post-MI | Outcomes |
|---|---|---|---|---|---|
| REGEN-AMI89 | AMI | BMC | IC | < 6 h | Recruiting—Assessing safety & efficacy in anterior AMI |
| Allogeneic MPCs after AMI90 | AMI | MPC (Allogeneic) | Transendocardial | 2–10 days | Recruiting—Assessing safety & efficacy |
| Prochymal after AMI91 | AMI | MPC (Allogeneic) | IV | < 7 days | Ongoing—Assessing LVESV |
| ADVANCE92 | AMI | ASC | IC | > 1 day | Recruiting—Assessing safety & efficacy |
| BAMI93 | AMI | BMC | IC | < 5 days | Not yet recruiting—Assessing safety and mortality reduction |
| ALLSTAR94 | AMI | CDC (Allogeneic) | IC | 1–12 months | Recruiting—Assessing safety and efficacy |
| REVITALIZE95 | HF | MSC | IC | Not specified | Ongoing—Assessing safety & feasibility |
| PERFECT96 | HF | BMC CD133+ | Transendocardial with CABG | Not specified | Recruiting—Assessing efficacy |
| REGEN-IHD97 | HF | BMC | G-CSF mobilization vs. IC vs. Transendocardial | Not specified | Ongoing—Comparing three different delivery routes |
| IMPACT-CABG98 | HF | CD133+ | Transendocardial with CABG | Not specified | Recruiting—Assessing efficacy |
| STOP-HF99 | HF | JVS-100 | Endomyocardial | Not specified | Ongoing—Assessing safety and efficacy |
| REGENERATE-DCM100 | DCM | BMC + G-CSF | IC | Not applicable | Recruiting—Assessing efficacy & safety |
| Long-Term Evaluation of Patients Receiving BMC Administration for Heart Disease101 | AMI, HF, DCM | BMC | IC | Not specified | Recruiting—Assessing long-term effects up to 10 years after transplantation |
AMI acute myocardial infarction; BMC bone marrow-derived cells; IC intracoronary; MPC mesenchymal precursor cells; IV intravenous; LVESV left ventricular end-systolic volumes; ASC adipose-derived stem cells; CDC cardiosphere-derived cells; HF heart failure; MSC mesenchymal stem cells; CABG coronary artery bypass graft; G-CSF granulocyte colony stimulating factor; DCM dilated cardiomyopathy